Table 5.
Postoperative pathologic staging in patients who underwent surgery
| Pathologic stage | FEC arm [cases (%)] | PE arm [cases (%)] | P value |
|---|---|---|---|
| Total | 132 | 130 | |
| pT stage | 0.001 | ||
| 0 | 11 (8.33) | 15 (11.53) | |
| DCIS | 7 (5.30) | 7 (5.38) | |
| 1 | 40 (30.30) | 62 (47.69) | |
| 2 | 57 (43.18) | 41 (31.54) | |
| 3 | 2 (1.52) | 2 (1.54) | |
| 4 | 15 (11.36) | 3 (2.31) | |
| pN stage | 0.001 | ||
| 0 | 46 (34.85) | 51 (39.23) | |
| 1 | 39 (29.55) | 39 (30.00) | |
| 2 | 25 (18.94) | 18 (13.85) | |
| 3 | 22 (16.67) | 22 (16.92) |
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, DCIS ductal carcinoma in situ